DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Alzheimer’s Disease – Current Treatment – Current Treatment: Physician Insights – Alzheimer’s Disease (US)
Alzheimer’s disease (AD) affects cognition and causes neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Disease-modifying therapy (DMT) is…
Alzheimer’s Disease – Geographic Focus: China – China In-Depth – Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by cognitive decline, memory impairment, and loss of functional independence. In China, current…
Alzheimer’s Disease – Access & Reimbursement – Access & Reimbursement – Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) are vying to capitalize on the potential for a disease-modifying therapy (DMT) in Alzheimer’s disease (AD), and…
